These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12728645)

  • 1. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Jan; 28(ACS-2):1-32. PubMed ID: 12728645
    [No Abstract]   [Full Text] [Related]  

  • 2. An advisory committee statement (ACS). National Advisory Committee on Immunization (NACI). Statement on smallpox vaccination.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Jan; 28(ACS-1):1-12. PubMed ID: 12728646
    [No Abstract]   [Full Text] [Related]  

  • 3. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2006 May; 32(ACS-4):1-6. PubMed ID: 16718922
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Supplementary statement on influenza vaccination: continued use of Fluviral influenza vaccine in the 2000-2001 season.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2001 Jan; 27():1-3. PubMed ID: 11227823
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pneumococcal vaccine for all children].
    Paré R; Pilon PA
    Perspect Infirm; 2005; 2(5):30-1. PubMed ID: 15962532
    [No Abstract]   [Full Text] [Related]  

  • 8. An advisory committee statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2003-2004 season.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2003 Aug; 29():1-20. PubMed ID: 12961958
    [No Abstract]   [Full Text] [Related]  

  • 9. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with pneumococcal conjugate vaccine in Norway.
    Aaberge IS
    Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal vaccine: to vaccinate or to revaccinate--that is the question.
    Uiterwyk SH
    Med Health R I; 2004 Mar; 87(3):68-71. PubMed ID: 15085683
    [No Abstract]   [Full Text] [Related]  

  • 12. Guidelines for Childhood Immunization Practices. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI).
    Can Commun Dis Rep; 1997 Dec; 23():1-12. PubMed ID: 9447783
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination.
    Rückinger S; von Kries R; Reinert RR; van der Linden M; Siedler A
    Vaccine; 2008 Jul; 26(32):3984-6. PubMed ID: 18495301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases.
    Rendi-Wagner P; Paulke-Korinek M; Kundi M; Burgmann H; Georgopoulos A; Vécsei A; Kollaritsch H
    Vaccine; 2009 Jun; 27(30):3963-8. PubMed ID: 19393711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An advisory committee statement (ACS). National Advisory Committee on Immunization (NACI). NACI update to statement on varicella vaccine.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Feb; 28(ACS-3):1-7. PubMed ID: 11875774
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased incidence of pneumococcal bloodstream infections.
    Rodríguez-Créixems M; Bertó J; Muñoz P; Alonso R; Alcalá L; Bouza E
    Pediatr Infect Dis J; 2003 Jul; 22(7):661-3. PubMed ID: 12886897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme.
    Bergsaker MA; Feiring B
    Euro Surveill; 2006 Feb; 11(2):E060202.5. PubMed ID: 16804205
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.